Mirae Asset Healthcare Fund vs Tata India Pharma & Healthcare Fund
Direct Plan, Growth option · Data as on 30-10-2026
Mirae Asset Healthcare Fund is a Thematic fund and Tata India Pharma & Healthcare Fund is a Thematic fund. In the 3 years to 30-10-2026, Mirae Asset Healthcare Fund (Direct) returned 23.9% a year and Tata India Pharma & Healthcare Fund (Direct) returned 19.3% a year. Mirae Asset Healthcare Fund charges 0.62% a year and Tata India Pharma & Healthcare Fund 1.10% (Direct plans). Their portfolios overlap 48.7%: they hold 19 of the same securities.
Mirae Asset Healthcare Fund
Thematic
- 3 year return
- 23.9%
- Expense ratio
- 0.62%
- NAV
- ₹51.66
Tata India Pharma & Healthcare Fund
Thematic
- 3 year return
- 19.3%
- Expense ratio
- 1.10%
- NAV
- ₹37.77
Which is better, Mirae Asset Healthcare or Tata India Pharma & Healthcare? Key differences
It depends on what you want from the fund. These are the differences in numbers, from the data on this page.
- Mirae Asset Healthcare returned more over 5 years: 16.6% a year against 14.9%.
- Mirae Asset Healthcare returned more over 3 years: 23.9% a year against 19.3%.
- Mirae Asset Healthcare costs less: 0.62% a year against 1.10% (Direct plans).
- Tata India Pharma & Healthcare swung less over 3 years: a standard deviation of 13.2% a year against 14.1%.
- Tata India Pharma & Healthcare fell less in its worst fall since 03-07-2018: −18.5% against −20.0%.
- Mirae Asset Healthcare is the larger fund: ₹3,494 Cr against ₹1,511 Cr.
- Their portfolios overlap 48.7%: 19 of the same holdings.
Past returns do not promise future returns. This page is information, not investment advice.
Key facts
From each fund's scheme summary document and AMFI
| Fact | Mirae Asset Healthcare Fund | Tata India Pharma & Healthcare Fund |
|---|---|---|
| Fund house | Mirae Asset Mutual Fund | Tata Mutual Fund |
| Category | Thematic | Thematic |
| AUM | ₹3,494 Cr (30-09-2026) | ₹1,511 Cr (30-09-2026) |
| NAV | ₹51.66 (Direct) | ₹37.77 (Direct) |
| Expense ratio (Direct) | 0.62% | 1.10% |
| Expense ratio (Regular) | 2.05% | 2.42% |
| Riskometer | Very High | Very High |
| Benchmark | BSE Healthcare TRI | BSE Healthcare TRI |
| Launch date | 02-07-2018 | 28-12-2015 |
| Minimum investment | ₹5,000 | ₹5,000 |
| Lock in | None | None |
| Fund managers | Vrijesh Kasera, Tanmay Mehta | Rajat Srivastava |
| Exit load | If redeemed within 1 month (30 days) from the date of allotment: 1% If redeemed after 1 month (30 days) from the date of allotment: NIL | 0.25% of NAV if redeemed /switched out before 30 days from the date of allotment. |
Mirae Asset Healthcare vs Tata India Pharma & Healthcare: Returns Comparison
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Fund | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| Mirae Asset Healthcare Fund (Direct) | +1.18% | +0.66% | +14.13% | +18.44% | +23.86% | +16.63% | -- |
| Tata India Pharma & Healthcare Fund (Direct) | −1.40% | −5.00% | +6.91% | +4.28% | +19.28% | +14.93% | +14.64% |
| Thematic average | −2.09% | −4.52% | +0.86% | −1.22% | +13.76% | +11.62% | +13.76% |
Category average: the average of the 235 Thematic funds, same plan type.
Mirae Asset Healthcare vs Tata India Pharma & Healthcare: Year-wise Returns
| Year | Mirae AssetMirae Asset Healthcare | Tata India Pharma &Tata India Pharma & Healthcare | BSE Healthcare TRI |
|---|---|---|---|
| 2026to date | +20.52% | +6.77% | +15.08% |
| 2025 | −1.99% | −3.47% | −2.72% |
| 2024 | +41.20% | +42.48% | +44.30% |
| 2023 | +36.06% | +38.59% | +37.97% |
| 2022 | −10.47% | −6.64% | −11.50% |
| 2021 | +28.58% | +20.88% | +21.54% |
Mirae Asset Healthcare vs Tata India Pharma & Healthcare: Rolling Returns
Every holding period of both funds, against BSE Healthcare TRI, the benchmark of both
Rolling returns
Every 3-year holding period, 1,311 of them, one for each trading day from 05-07-2021 to 30-10-2026: the yearly return (CAGR) of each, plotted on the day it ended. One lucky or unlucky start day cannot flatter or hide a fund.
Mirae Asset Healthcare Fund (Direct)
Tata India Pharma & Healthcare Fund (Direct)
BSE Healthcare TRI
to
Dec 2021Nov 2019
to
Nov 2022Sept 2020
to
Sept 2023Aug 2021
to
Aug 2024Jul 2022
to
Jul 2025May 2023
to
May 2026
How the periods spread
| Fund | Below 0% | 0-5% | 5-10% | 10-15% | 15-20% | 20-25% | Above 25% | Mean | Median | Lowest | Highest | Beat benchmark |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mirae Asset Healthcare | 0.0 | 0.0 | 0.0 | 1.4 | 29.5 | 30.6 | 38.5 | 23.8% | 23.2% | 14.3% | 35.8% | 74% |
| Tata India Pharma & Healthcare | 0.0 | 0.0 | 0.0 | 0.8 | 25.4 | 47.9 | 25.9 | 22.4% | 23.0% | 14.5% | 30.5% | 76% |
| BSE Healthcare TRI | 0.0 | 0.0 | 0.0 | 12.1 | 28.8 | 46.5 | 12.7 | 20.6% | 20.9% | 12.0% | 28.8% | -- |
The table shows the % of periods in each return band; a darker cell holds more of them. Lumpsum: the yearly rate (CAGR) from a period's first NAV to its last. SIP: the XIRR of the monthly instalments. The benchmark is BSE Healthcare TRI, over the same periods. "Beat benchmark" counts the periods in which the fund did better. Every fund is measured over the days all of them have, from 03-07-2018. Past returns do not promise future returns.
Mirae Asset Healthcare vs Tata India Pharma & Healthcare: SIP and Lumpsum Returns
What the same monthly or one-time investment would be worth in each fund today, from their own NAV history
Growth of an investment
₹10,000 on the first trading day of every month, from 03-07-2018 to 30-10-2026: 100 instalments, ₹10,00,000 in all.
| Investment | Invested | Value now | Gain | Return a year |
|---|---|---|---|---|
| Mirae Asset HealthcareMirae Asset Healthcare Fund (Direct) | ₹10,00,000 | ₹25,53,977 | ₹15,53,977 | 21.8% |
| Tata India Pharma & HealthcareTata India Pharma & Healthcare Fund (Direct) | ₹10,00,000 | ₹22,04,749 | ₹12,04,749 | 18.4% |
Mirae Asset HealthcareMirae Asset Healthcare Fund (Direct)
Tata India Pharma & HealthcareTata India Pharma & Healthcare Fund (Direct)
Amount invested
From each plan's published NAV (Growth option), over the same days. Return a year: XIRR for a SIP, CAGR for a lumpsum, shown for a year or more. It does not include exit load, stamp duty or tax. Past returns do not promise future returns.
Mirae Asset Healthcare vs Tata India Pharma & Healthcare: Risk and Drawdowns
How much each fund swings, and the worst fall over the same days
Risk and return
| Measure | Mirae Asset Healthcare Fund (Direct) | Tata India Pharma & Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +18.44% | +4.28% |
| Standard deviation | 13.74% | 11.99% |
| Sharpe ratio | 0.96 | -0.08 |
| Sortino ratio | 1.43 | -0.11 |
| Maximum drawdown | −9.1% (23-10-2026) | −11.0% (23-10-2026) |
| Beta | 0.99 | 0.82 |
| Alpha | +6.18% | −6.83% |
From daily NAVs, 30-10-2025 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | Mirae Asset Healthcare Fund (Direct) | Tata India Pharma & Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +23.86% | +19.28% |
| Standard deviation | 14.12% | 13.21% |
| Sharpe ratio | 1.26 | 1.00 |
| Sortino ratio | 1.80 | 1.43 |
| Maximum drawdown | −15.9% (28-02-2025) | −16.8% (28-02-2025) |
| Beta | 0.97 | 0.89 |
| Alpha | +1.28% | −1.91% |
From daily NAVs, 30-10-2023 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | Mirae Asset Healthcare Fund (Direct) | Tata India Pharma & Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +16.63% | +14.93% |
| Standard deviation | 13.69% | 12.92% |
| Sharpe ratio | 0.79 | 0.71 |
| Sortino ratio | 1.13 | 1.01 |
| Maximum drawdown | −18.5% (17-06-2022) | −16.8% (28-02-2025) |
| Beta | 0.95 | 0.89 |
| Alpha | +1.47% | +0.41% |
From daily NAVs, 29-10-2021 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | Mirae Asset Healthcare Fund (Direct) | Tata India Pharma & Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +21.71% | +13.01% |
| Standard deviation | 15.56% | 15.08% |
| Sharpe ratio | 1.06 | 0.50 |
| Sortino ratio | 1.54 | 0.72 |
| Maximum drawdown | −20.0% (23-03-2020) | −19.8% (21-08-2017) |
| Beta | 0.92 | 0.87 |
| Alpha | +5.56% | +2.53% |
From daily NAVs, 03-07-2018 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
Mirae Asset Healthcare Fund (Direct)
Tata India Pharma & Healthcare Fund (Direct)
BSE Healthcare TRI
| Fund | Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today |
|---|---|---|---|---|---|---|
| Mirae Asset Healthcare Fund (Direct) | −20.0% | 20-02-2020 | 23-03-2020 | 08-04-2020 | 16 days | −2.8% |
| Tata India Pharma & Healthcare Fund (Direct) | −18.5% | 19-02-2020 | 23-03-2020 | 08-04-2020 | 16 days | −6.0% |
| BSE Healthcare TRI | −31.6% | 07-09-2018 | 23-03-2020 | 05-06-2020 | 2 months | −3.8% |
From daily values since 03-07-2018, the first day every fund has.
Rolling standard deviation
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 1-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
Mirae Asset Healthcare Fund (Direct)
Tata India Pharma & Healthcare Fund (Direct)
BSE Healthcare TRI
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 3-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
Mirae Asset Healthcare Fund (Direct)
Tata India Pharma & Healthcare Fund (Direct)
BSE Healthcare TRI
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 5-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
Mirae Asset Healthcare Fund (Direct)
Tata India Pharma & Healthcare Fund (Direct)
BSE Healthcare TRI
Against BSE Healthcare TRI
| Fund | Up capture | Down capture | Tracking error |
|---|---|---|---|
| Mirae Asset Healthcare Fund (Direct) | 100% | 78% | 3.85% |
| Tata India Pharma & Healthcare Fund (Direct) | 92% | 78% | 4.53% |
From month-end values since 03-07-2018. Up capture: a fund's average month when the benchmark rose, as % of the benchmark's; above 100% it gained more. Down capture: the same for months the benchmark fell; below 100% it fell less. Tracking error: how far the monthly returns strayed from the benchmark's, a year; an index fund aims near 0.
Mirae Asset Healthcare vs Tata India Pharma & Healthcare: Portfolio Overlap
From each fund's latest monthly portfolio: Mirae Asset Healthcare Fund, September 2026; Tata India Pharma & Healthcare Fund, September 2026
Holdings in common
- Overlap
- 48.7%
- Held by both
- 19
- Only in Mirae Asset Healthcare
- 11
- Only in Tata India Pharma & Healthcare
- 22
| Security | % of Mirae Asset Healthcare | % of Tata India Pharma & Healthcare |
|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 10.15% | 7.99% |
| Divi's Laboratories Ltd. | 9.79% | 5.68% |
| Dr. Reddy's Laboratories Ltd. | 4.84% | 4.65% |
| Apollo Hospitals Enterprise Ltd. | 5.62% | 4.36% |
| Torrent Pharmaceuticals Ltd. | 6.80% | 3.76% |
| Cipla Ltd. | 2.63% | 4.22% |
| Sai Life Sciences Ltd. | 3.23% | 2.60% |
| Alkem Laboratories Ltd. | 3.76% | 2.36% |
| Max Healthcare Institute Ltd. | 2.35% | 3.71% |
| Lupin Ltd. | 2.27% | 3.14% |
| Fortis Healthcare Ltd. | 2.94% | 1.95% |
| Dr. Lal Path labs Ltd. | 2.90% | 1.76% |
| Aster DM Quality Care Ltd. | 3.32% | 1.67% |
| Anthem Biosciences Ltd. | 0.93% | 2.57% |
| IPCA Laboratories Ltd. | 3.39% | 0.91% |
| Symbiotec Pharmalab Ltd | 1.60% | 0.87% |
| Mankind Pharma Ltd. | 2.24% | 0.77% |
| Biocon Ltd. | 2.00% | 0.69% |
| Molbio Diagnostics Ltd. | 1.77% | 0.54% |
Overlap: for each holding both funds own, the smaller of its two weights, added up. 48.7% means 48.7% of each fund's money sits in positions the other also holds. Matched by ISIN. Cash and hedged positions are left out.
Largest holdings only in Mirae Asset Healthcare Fund
| Security | % of fund |
|---|---|
| Laurus Labs Ltd. | 5.51% |
| Glenmark Pharmaceuticals Ltd. | 4.78% |
| Aurobindo Pharma Ltd. | 3.78% |
| Krishna Institute of Medical Sciences Ltd. | 3.39% |
| Onesource Specialty Pharma Ltd. | 3.01% |
Largest holdings only in Tata India Pharma & Healthcare Fund
| Security | % of fund |
|---|---|
| ABBOTT INDIA LTD | 5.94% |
| HEALTHCARE GLOBAL ENTERPRISES LTD | 5.92% |
| RAINBOW CHILDRENS MEDICARE LTD | 4.30% |
| BAYER CROPSCIENCE LTD | 2.96% |
| SYNGENE INTERNATIONAL LTD | 2.85% |
Asset and sector split
Share of each fund, from its latest monthly portfolio
Asset allocation
| Asset | Mirae Asset Healthcare | Tata India Pharma & Healthcare |
|---|---|---|
| Equity | 100.0% | 99.7% |
| Debt | 0.0% | 0.0% |
| Cash and others | 0.0% | 0.3% |
Market cap of stocks
| Market cap | Mirae Asset Healthcare | Tata India Pharma & Healthcare |
|---|---|---|
| Large Cap | 35.0% | 26.0% |
| Mid Cap | 42.1% | 33.9% |
| Small Cap | 19.5% | 37.0% |
| Not on AMFI's list | 3.4% | 2.9% |
Share of the whole fund. Groups follow AMFI's latest list: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Largest sectors
| Sector | Mirae Asset Healthcare | Tata India Pharma & Healthcare |
|---|---|---|
| Pharmaceuticals & Biotechnology | 75.8% | 60.6% |
| Healthcare Services | 20.5% | 27.8% |
| Fertilizers & Agrochemicals | 0.0% | 6.9% |
| Chemicals & Petrochemicals | 1.9% | 2.6% |
| Healthcare Equipment & Supplies | 1.8% | 0.5% |
| Personal Products | 0.0% | 1.2% |
The six largest sectors of each fund's stocks, % of the fund.
Mirae Asset Healthcare vs Tata India Pharma & Healthcare: Expense Ratio
What each plan charges a year, from AMFI's expense ratio file
| Charge | Mirae Asset Healthcare Fund | Tata India Pharma & Healthcare Fund |
|---|---|---|
| Total expense ratio (Direct) | 0.62% | 1.10% |
| Base expense ratio (Direct) | 0.45% | 0.64% |
| Total expense ratio (Regular) | 2.05% | 2.42% |
| Base expense ratio (Regular) | 1.66% | 1.82% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, transaction costs, and levies with GST.
More comparisons
Each fund against the others of its category
Compare Mirae Asset Healthcare with
Compare Tata India Pharma & Healthcare with
- Tata India Pharma & Healthcare vs Nippon India Taiwan Equity
- Tata India Pharma & Healthcare vs HDFC Defence
- Tata India Pharma & Healthcare vs HDFC Pharma and Healthcare
- Tata India Pharma & Healthcare vs SBI Healthcare Opportunities
- Tata India Pharma & Healthcare vs Aditya Birla Sun Life International Equity
Mirae Asset Healthcare Fund vs Tata India Pharma & Healthcare Fund: Frequently Asked Questions
What is the difference between Mirae Asset Healthcare Fund and Tata India Pharma & Healthcare Fund?
Mirae Asset Healthcare Fund is a Thematic fund, Tata India Pharma & Healthcare Fund is a Thematic fund, run by Mirae Asset Mutual Fund and Tata Mutual Fund. Their portfolios overlap 48.7%. Mirae Asset Healthcare Fund charges 0.62% a year and Tata India Pharma & Healthcare Fund 1.10%.
Which has given higher returns, Mirae Asset Healthcare Fund or Tata India Pharma & Healthcare Fund?
Over 1 year: Mirae Asset Healthcare Fund +18.44%, Tata India Pharma & Healthcare Fund +4.28%. Over 3 years: Mirae Asset Healthcare Fund +23.86% a year, Tata India Pharma & Healthcare Fund +19.28% a year. Over 5 years: Mirae Asset Healthcare Fund +16.63% a year, Tata India Pharma & Healthcare Fund +14.93% a year. As on 30-10-2026. Past returns do not promise future returns.
Which has the lower expense ratio, Mirae Asset Healthcare Fund or Tata India Pharma & Healthcare Fund?
Mirae Asset Healthcare Fund charges less: 0.62% a year against 1.10%. These are the Direct plans' total expense ratios reported to AMFI.
How much do Mirae Asset Healthcare Fund and Tata India Pharma & Healthcare Fund overlap?
48.7%. They hold 19 of the same securities, the largest shared ones being SUNPHARMA, DIVISLAB, DRREDDY. From each fund's latest monthly portfolio.
Which is riskier, Mirae Asset Healthcare Fund or Tata India Pharma & Healthcare Fund?
On SEBI's riskometer, Mirae Asset Healthcare Fund is rated Very High and Tata India Pharma & Healthcare Fund Very High. Over 3 years, the standard deviation of daily returns was 14.12% and 13.21% a year.
Which is better for SIP, Mirae Asset Healthcare Fund or Tata India Pharma & Healthcare Fund?
Over the last 5 years, a monthly SIP of ₹10,000 from 01-10-2021 to 30-10-2026 grew to ₹10,11,191 in Mirae Asset Healthcare Fund (XIRR 20.0% a year) and ₹9,10,986 in Tata India Pharma & Healthcare Fund (XIRR 15.8% a year). Both received 61 instalments. Past returns do not promise future returns.
Can I invest in both Mirae Asset Healthcare Fund and Tata India Pharma & Healthcare Fund?
Yes. 48.7% of each fund's money sits in the same holdings, so a large part of the two investments would move together.
Who manages Mirae Asset Healthcare Fund and Tata India Pharma & Healthcare Fund?
Mirae Asset Healthcare Fund: Vrijesh Kasera, Tanmay Mehta. Tata India Pharma & Healthcare Fund: Rajat Srivastava.
Sources: NAV and expense ratio from AMFI. Holdings from each fund house's monthly portfolio statement. Fund facts from each scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.